IRIS
AMODIO, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.061
AS - Asia 1.037
EU - Europa 960
SA - Sud America 18
Continente sconosciuto - Info sul continente non disponibili 16
AF - Africa 10
OC - Oceania 2
Totale 4.104
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.012
SG - Singapore 704
IT - Italia 554
CN - Cina 259
SE - Svezia 189
GB - Regno Unito 89
CA - Canada 48
DE - Germania 26
RO - Romania 26
IN - India 21
EU - Europa 15
BR - Brasile 13
HK - Hong Kong 13
CZ - Repubblica Ceca 11
NL - Olanda 11
IR - Iran 9
RU - Federazione Russa 9
EG - Egitto 8
JP - Giappone 8
UA - Ucraina 8
FR - Francia 6
AT - Austria 5
CH - Svizzera 5
GR - Grecia 5
YE - Yemen 5
CL - Cile 4
FI - Finlandia 4
PK - Pakistan 4
EE - Estonia 3
ES - Italia 3
MY - Malesia 3
AU - Australia 2
BD - Bangladesh 2
DK - Danimarca 2
TR - Turchia 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
IL - Israele 1
KW - Kuwait 1
MK - Macedonia 1
MX - Messico 1
NO - Norvegia 1
PH - Filippine 1
PL - Polonia 1
PT - Portogallo 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 4.104
Salva come PNG Salva come JPEG
Città #
Chandler 388
Singapore 246
Santa Clara 219
Lawrence 189
Princeton 189
Milan 188
Catanzaro 134
Wilmington 106
London 82
Chicago 79
Beijing 72
Des Moines 57
Ashburn 52
Ottawa 45
Shanghai 24
Boardman 23
Redwood City 20
Guangzhou 16
Horia 14
Hong Kong 13
Norwalk 13
Pune 12
Rome 11
Hanover 10
Olomouc 10
Redmond 10
Timisoara 10
Cosenza 9
Naples 9
Bari 8
Ann Arbor 7
Jiaxing 7
Lamezia Terme 7
San Jose 7
San Nicola Manfredi 7
Settingiano 7
Shenzhen 7
Hefei 6
Palermo 6
Parma 6
Reggio Calabria 6
West Jordan 6
Andover 5
Augusta 5
Aversa 5
Los Angeles 5
Munich 5
Nanjing 5
New York 5
Sanaa 5
Caserta 4
Council Bluffs 4
Hebei 4
Helsinki 4
Novokuznetsk 4
Taranto 4
Xi'an 4
Ahmedabad 3
Cetraro 3
Fayetteville 3
Masera 3
Napoli 3
San Mateo 3
São Paulo 3
Treviso 3
Zhengzhou 3
6th of October City 2
Apo 2
Assago 2
Benevento 2
Brugnera 2
Cairo 2
Ceglie Del Campo 2
Diemen 2
Fiumicino 2
Fuzhou 2
Genazzano 2
Grottaglie 2
Irsina 2
Islamabad 2
Jinhua 2
Lahore 2
Leawood 2
Mountain View 2
Petersham 2
Portici 2
Quanzhou 2
Roccella Ionica 2
San Francisco 2
San Polo di Torrile 2
Shantou 2
Shenyang 2
Sistan 2
Spezzano della Sila 2
Stalettì 2
Toronto 2
Trapani 2
Vallefiorita 2
Vienna 2
Vigliano Biellese 2
Totale 2.500
Salva come PNG Salva come JPEG
Nome #
miR-22 suppresses DNA ligase III addiction in multiple myeloma 73
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 60
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 58
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 51
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 49
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 47
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 46
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 45
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 44
TARGETING OF DEREGULATED LNCRNA NEAT1 AFFECTS MULTIPLE MYELOMA ACTIVITY 44
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy 44
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells 43
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer 42
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 42
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 41
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer 40
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 39
Early hematopoietic zinc finger protein, a novel transcription co-factor with a potential role in haematopoietic homeostasis and leukaemogenesis 39
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 39
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 38
P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS 38
Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches 37
Radiation induced by-stander effect: possible RNA implication in DNA damage transmission? 37
Early Hematopoietic Zinc Finger protein (EHZF), the human homologue to Evi3, is highly expressed in primitive human hematopoietic cells 37
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 36
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 35
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 35
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 34
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 34
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats 34
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma 33
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. 33
In Vitro Silencing of lncRNAs Using LNA GapmeRs 33
Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction 33
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 32
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 30
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 30
A 13 mer LNA miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 30
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 30
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 29
Contribution of PKB/AKT signaling to thyroid cancer 29
Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells 29
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 28
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 28
Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment 28
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 28
In vitro and vivo activity against multiple myeloma cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor 28
Early hematopoietic zinc finger protein - zinc finger protein 521 (EHZF/ZNF521): a candidate regulator of diverse immature cells 28
In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients 28
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 28
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network 28
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 27
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 27
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 27
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma 26
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 26
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 26
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 25
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 25
Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma 25
Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart 25
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 24
Functional Analysis of microRNA in Multiple Myeloma 24
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 24
Early Hematopoietic Zinc Finger (EHZF/ZNF521) prevents tumor cell recognition by Natural Killer Cells 24
Activating E17K mutation in the gene encoding the protein kinase B/AKT in squamous cell carcinoma of the lung 24
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 24
Znf521 enhances mll‐af9‐dependent hematopoietic stem cell transformation in acute myeloid leukemias by altering the gene expression landscape† 24
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells 24
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 24
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 23
Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors 23
Biological Insights into Myeloma and Other B Cell Malignancies 23
Chromofungin, CgA47-66-derived peptide, produces basal cardiac effects and postconditioning cardioprotective action during ischemia/reperfusion injury 23
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients 22
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma 22
The non-coding RNA landscape of plasma cell dyscrasias 22
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. 21
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 21
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. 21
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 21
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. 20
Early Hematopoietic Zinc Finger protein (EHZF), a novel co-transcription factor: functional properties, expression in myelogenous leukaemias and interactions with histone deacetylases 20
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 19
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 19
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 19
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 19
Challenges in multiple myeloma chemoprevention: potential role of natural, synthetic and endogenous molecules 19
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 18
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth 18
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 18
Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs 18
Contribution of PKB/AKT signaling to thyroid cancer 17
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma 17
ZINC FINGER PROTEIN 521 (EHZF/ZNF521) ANTAGONIZES EARLY B-CELL FACTOR 1 AND MODULATES THE B-LYMPHOID DIFFERENTIATION OF PRIMARY HEMATOPOIETIC PROGENITORS 17
Early hematopoietic zinc finger (EHZF), a multifunctional transcription co-factor expressed in human early hematopoietic cells and AML blasts 17
Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma 17
The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1 17
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells 17
Current status and future perspectives on therapeutic potential of apigenin: Focus on metabolic-syndrome-dependent organ dysfunction 17
Totale 2.964
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.228
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202063 0 0 0 0 0 0 0 0 0 0 13 50
2020/2021337 19 3 14 14 34 21 20 14 54 45 72 27
2021/2022569 23 2 5 154 38 13 24 113 54 61 71 11
2022/20231.183 386 64 71 68 100 93 5 87 163 51 70 25
2023/2024515 113 73 34 42 28 129 13 8 2 14 19 40
2024/20251.487 321 95 65 58 151 302 44 51 266 130 4 0
Totale 4.334